Literature DB >> 28986986

Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva.

Michael R Convente1,2, Salin A Chakkalakal1,2, EnJun Yang3, Robert J Caron1,2, Deyu Zhang1,2, Taku Kambayashi3, Frederick S Kaplan1,2,4, Eileen M Shore1,2,5.   

Abstract

Heterotopic ossification (HO) is a clinical condition that often reduces mobility and diminishes quality of life for affected individuals. The most severe form of progressive HO occurs in those with fibrodysplasia ossificans progressiva (FOP; OMIM #135100), a genetic disorder caused by a recurrent heterozygous gain-of-function mutation (R206H) in the bone morphogenetic protein (BMP) type I receptor ACVR1/ALK2. In individuals with FOP, episodes of HO frequently follow injury. The first sign of active disease is commonly an inflammatory "flare-up" that precedes connective tissue degradation, progenitor cell recruitment, and endochondral HO. We used a conditional-on global knock-in mouse model expressing Acvr1R206H (referred to as Acvr1cR206H/+ ) to investigate the cellular and molecular inflammatory response in FOP lesions following injury. We found that the Acvr1 R206H mutation caused increased BMP signaling in posttraumatic FOP lesions and early divergence from the normal skeletal muscle repair program with elevated and prolonged immune cell infiltration. The proinflammatory cytokine response of TNFα, IL-1β, and IL-6 was elevated and prolonged in Acvr1cR206H/+ lesions and in Acvr1cR206H/+ mast cells. Importantly, depletion of mast cells and macrophages significantly impaired injury-induced HO in Acvr1cR206H/+ mice, reducing injury-induced HO volume by ∼50% with depletion of each cell population independently, and ∼75% with combined depletion of both cell populations. Together, our data show that the immune system contributes to the initiation and development of HO in FOP. Further, the expression of Acvr1R206H in immune cells alters cytokine expression and cellular response to injury and unveils novel therapeutic targets for treatment of FOP and nongenetic forms of HO.
© 2017 American Society for Bone and Mineral Research. © 2017 American Society for Bone and Mineral Research.

Entities:  

Keywords:  ACVR1; BMP; BONE MORPHOGENETIC PROTEIN SIGNALING; CHRONIC INFLAMMATION; FIBRODYSPLASIA OSSIFICANS PROGRESSIVA; FOP; HETEROTOPIC OSSIFICATION; TISSUE INJURY

Mesh:

Substances:

Year:  2018        PMID: 28986986      PMCID: PMC7737844          DOI: 10.1002/jbmr.3304

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  93 in total

Review 1.  Development of mast cells and importance of their tryptase and chymase serine proteases in inflammation and wound healing.

Authors:  Jeffrey Douaiher; Julien Succar; Luca Lancerotto; Michael F Gurish; Dennis P Orgill; Matthew J Hamilton; Steven A Krilis; Richard L Stevens
Journal:  Adv Immunol       Date:  2014       Impact factor: 3.543

2.  An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva.

Authors:  Salin A Chakkalakal; Deyu Zhang; Andria L Culbert; Michael R Convente; Robert J Caron; Alexander C Wright; Andrew D A Maidment; Frederick S Kaplan; Eileen M Shore
Journal:  J Bone Miner Res       Date:  2012-08       Impact factor: 6.741

Review 3.  Adipokines in health and disease.

Authors:  Mathias Fasshauer; Matthias Blüher
Journal:  Trends Pharmacol Sci       Date:  2015-05-25       Impact factor: 14.819

4.  Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo.

Authors:  Michele A Grimbaldeston; Ching-Cheng Chen; Adrian M Piliponsky; Mindy Tsai; See-Ying Tam; Stephen J Galli
Journal:  Am J Pathol       Date:  2005-09       Impact factor: 4.307

5.  Burn injury enhances bone formation in heterotopic ossification model.

Authors:  Jonathan R Peterson; Sara De La Rosa; Hongli Sun; Oluwatobi Eboda; Katherine E Cilwa; Alexis Donneys; Michael Morris; Steven R Buchman; Paul S Cederna; Paul H Krebsbach; Stewart C Wang; Benjamin Levi
Journal:  Ann Surg       Date:  2014-05       Impact factor: 12.969

6.  Statins decrease expression of the proinflammatory neuropeptides calcitonin gene-related peptide and substance P in sensory neurons.

Authors:  Robert C Bucelli; Eugene A Gonsiorek; Woo-Yang Kim; Donald Bruun; Richard A Rabin; Dennis Higgins; Pamela J Lein
Journal:  J Pharmacol Exp Ther       Date:  2007-12-13       Impact factor: 4.030

7.  Chemokine receptor CX3CR1 mediates skin wound healing by promoting macrophage and fibroblast accumulation and function.

Authors:  Yuko Ishida; Ji-Liang Gao; Philip M Murphy
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

Review 8.  Cytokines in muscle damage.

Authors:  Anastassios Philippou; Maria Maridaki; Apostolos Theos; Michael Koutsilieris
Journal:  Adv Clin Chem       Date:  2012       Impact factor: 5.394

Review 9.  Mast cell mediators: their differential release and the secretory pathways involved.

Authors:  Tae Chul Moon; A Dean Befus; Marianna Kulka
Journal:  Front Immunol       Date:  2014-11-14       Impact factor: 7.561

Review 10.  The neutrophil in vascular inflammation.

Authors:  Mia Phillipson; Paul Kubes
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

View more
  50 in total

Review 1.  Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva.

Authors:  Kelly L Wentworth; Umesh Masharani; Edward C Hsiao
Journal:  Br J Clin Pharmacol       Date:  2019-01-06       Impact factor: 4.335

2.  Elevated BMP and Mechanical Signaling Through YAP1/RhoA Poises FOP Mesenchymal Progenitors for Osteogenesis.

Authors:  Alexandra Stanley; Su-Jin Heo; Robert L Mauck; Foteini Mourkioti; Eileen M Shore
Journal:  J Bone Miner Res       Date:  2019-08-19       Impact factor: 6.741

3.  NF-κB/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification.

Authors:  Emilie Barruet; Blanca M Morales; Corey J Cain; Amy N Ton; Kelly L Wentworth; Tea V Chan; Tania A Moody; Mariëlle C Haks; Tom Hm Ottenhoff; Judith Hellman; Mary C Nakamura; Edward C Hsiao
Journal:  JCI Insight       Date:  2018-11-15

Review 4.  Inflammation in Fibrodysplasia Ossificans Progressiva and Other Forms of Heterotopic Ossification.

Authors:  Koji Matsuo; Robert Dalton Chavez; Emilie Barruet; Edward C Hsiao
Journal:  Curr Osteoporos Rep       Date:  2019-12       Impact factor: 5.096

5.  Identification of the Identical Human Mutation in ACVR1 in 2 Cats With Fibrodysplasia Ossificans Progressiva.

Authors:  Margret L Casal; Julie B Engiles; Maja Zakošek Pipan; Asaf Berkowitz; Yael Porat-Mosenco; Wilfried Mai; Kirsten Wurzburg; Mei-Qi Xu; Robyn Allen; Patricia A ODonnell; Paula S Henthorn; Keith Thompson; Eileen M Shore
Journal:  Vet Pathol       Date:  2019-04-22       Impact factor: 2.221

Review 6.  Fibrodysplasia ossificans progressiva (FOP): A disorder of osteochondrogenesis.

Authors:  Frederick S Kaplan; Mona Al Mukaddam; Alexandra Stanley; O Will Towler; Eileen M Shore
Journal:  Bone       Date:  2020-07-27       Impact factor: 4.398

Review 7.  Granting immunity to FOP and catching heterotopic ossification in the Act.

Authors:  Frederick S Kaplan; Robert J Pignolo; Eileen M Shore
Journal:  Semin Cell Dev Biol       Date:  2015-12-17       Impact factor: 7.727

8.  Macrophage-derived neurotrophin-3 promotes heterotopic ossification in rats.

Authors:  Jie Zhang; Liang Wang; Jun Chu; Xiang Ao; Tao Jiang; Minjun Huang; Zhongmin Zhang
Journal:  Lab Invest       Date:  2020-01-02       Impact factor: 5.662

Review 9.  Osteoimmunology: evolving concepts in bone-immune interactions in health and disease.

Authors:  Masayuki Tsukasaki; Hiroshi Takayanagi
Journal:  Nat Rev Immunol       Date:  2019-06-11       Impact factor: 53.106

10.  ACVR1R206H extends inflammatory responses in human induced pluripotent stem cell-derived macrophages.

Authors:  Koji Matsuo; Abigail Lepinski; Robert D Chavez; Emilie Barruet; Ashley Pereira; Tania A Moody; Amy N Ton; Aditi Sharma; Judith Hellman; Kiichiro Tomoda; Mary C Nakamura; Edward C Hsiao
Journal:  Bone       Date:  2021-07-24       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.